194 related articles for article (PubMed ID: 33957388)
1. Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation.
Xu D; Sun D; Wang W; Peng X; Zhan Z; Ji Y; Shen Y; Geng M; Ai J; Duan W
Eur J Med Chem; 2021 Aug; 220():113497. PubMed ID: 33957388
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors.
Inoue S; Yamane Y; Tsukamoto S; Murai N; Azuma H; Nagao S; Nishibata K; Fukushima S; Ichikawa K; Nakagawa T; Hata Sugi N; Ito D; Kato Y; Goto A; Kakiuchi D; Ueno T; Matsui J; Matsushima T
Bioorg Med Chem Lett; 2021 Sep; 48():128247. PubMed ID: 34271070
[TBL] [Abstract][Full Text] [Related]
3. 4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors.
Tan L; Zhang Z; Gao D; Luo J; Tu ZC; Li Z; Peng L; Ren X; Ding K
J Med Chem; 2016 Jul; 59(14):6807-25. PubMed ID: 27379978
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells.
Shi X; Quan Y; Wang Y; Wang Y; Li Y
Bioorg Med Chem Lett; 2021 Feb; 33():127725. PubMed ID: 33316409
[TBL] [Abstract][Full Text] [Related]
5. Discovery of dual Axl/VEGF-R2 inhibitors as potential anti-angiogenic and anti-metastatic drugs for cancer chemotherapy.
Goff D; Zhang J; Heckrodt T; Yu J; Ding P; Singh R; Holland S; Li W; Irving M
Bioorg Med Chem Lett; 2017 Aug; 27(16):3766-3771. PubMed ID: 28711351
[TBL] [Abstract][Full Text] [Related]
6. Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.
Pavana RK; Choudhary S; Bastian A; Ihnat MA; Bai R; Hamel E; Gangjee A
Bioorg Med Chem; 2017 Jan; 25(2):545-556. PubMed ID: 27894589
[TBL] [Abstract][Full Text] [Related]
7. Recent discovery and development of AXL inhibitors as antitumor agents.
Liu Z; Chen L; Zhang J; Yang J; Xiao X; Shan L; Mao W
Eur J Med Chem; 2024 Jun; 272():116475. PubMed ID: 38714043
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of new Axl kinase inhibitors containing 1,3,4-oxadiazole acetamide moiety as novel linker.
Xu C; Han Y; Xu S; Wang R; Yue M; Tian Y; Li X; Zhao Y; Gong P
Eur J Med Chem; 2020 Jan; 186():111867. PubMed ID: 31757525
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of novel aminopyrimidinylisoindolines as AXL kinase inhibitors.
Choi MJ; Roh EJ; Hur W; Lee SH; Sim T; Oh CH; Lee SH; Kim JS; Yoo KH
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3761-3765. PubMed ID: 30340900
[TBL] [Abstract][Full Text] [Related]
12. The synthesis and bioactivity of pyrrolo[2,3-d]pyrimidine derivatives as tyrosine kinase inhibitors for NSCLC cells with EGFR mutations.
Xia Z; Huang R; Zhou X; Chai Y; Chen H; Ma L; Yu Q; Li Y; Li W; He Y
Eur J Med Chem; 2021 Nov; 224():113711. PubMed ID: 34315040
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.
Gangjee A; Namjoshi OA; Yu J; Ihnat MA; Thorpe JE; Warnke LA
Bioorg Med Chem; 2008 May; 16(10):5514-28. PubMed ID: 18467105
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship of 7-aryl-2-anilino-pyrrolopyrimidines as Mer and Axl tyrosine kinase inhibitors.
Chung SH; Park J; Lee JW; Song J; Jung D; Min KH
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1822-1833. PubMed ID: 32972253
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
[TBL] [Abstract][Full Text] [Related]
16. Development of the phenylpyrazolo[3,4-
Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
[No Abstract] [Full Text] [Related]
17. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
[TBL] [Abstract][Full Text] [Related]
18. Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.
Brasca MG; Nesi M; Avanzi N; Ballinari D; Bandiera T; Bertrand J; Bindi S; Canevari G; Carenzi D; Casero D; Ceriani L; Ciomei M; Cirla A; Colombo M; Cribioli S; Cristiani C; Della Vedova F; Fachin G; Fasolini M; Felder ER; Galvani A; Isacchi A; Mirizzi D; Motto I; Panzeri A; Pesenti E; Vianello P; Gnocchi P; Donati D
Bioorg Med Chem; 2014 Sep; 22(17):4998-5012. PubMed ID: 25009002
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor.
Zhang H; Peng X; Dai Y; Shao J; Ji Y; Sun Y; Liu B; Cheng X; Ai J; Duan W
J Med Chem; 2021 Apr; 64(7):3956-3975. PubMed ID: 33733758
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.
Wang Y; Liu WJ; Yin L; Li H; Chen ZH; Zhu DX; Song XQ; Cheng ZZ; Song P; Wang Z; Li ZG
Bioorg Med Chem Lett; 2018 Mar; 28(5):974-978. PubMed ID: 29429832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
